ミズーリ州における慢性リンパ性白血病の臨床試験
ミズーリ州内の拠点で、慢性リンパ性白血病に関する13件の研究が参加者を募集しています。
ミズーリ州内の都市
公式研究テキスト（英語）
Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL
- Saint Francis Medical Center, Cape Girardeau
- Siteman Cancer Center at Saint Peters Hospital, City of Saint Peters
- Siteman Cancer Center at West County Hospital, Creve Coeur
- 他11件
被験者募集中第3相
65歳以上 · 全性別 · 2026/10/02更新 · NCT07321652Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
- Mercy Oncology and Hematology - Clayton-Clarkson, Ballwin
- Central Care Cancer Center - Bolivar, Bolivar
- Cox Cancer Center Branson, Branson
- 他21件
被験者募集中観察研究健康なボランティア歓迎
40歳〜75歳 · 全性別 · 2026/10/02更新 · NCT05334069Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
- Saint Francis Medical Center, Cape Girardeau
- Saint Luke's Hospital, Chesterfield
- Parkland Health Center - Farmington, Farmington
- 他11件
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/30更新 · NCT04269902A Study of Tacabrutideg (BGB-16673) Compared to Investigator's Choice in Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Previously Exposed to Both Bruton Tyrosine Kinase (BTK) and B-cell Leukemia/Lymphoma 2 Protein (BCL2) Inhibitors
- St Lukes Center For Cancer Care, Chesterfield
- Oncology Hematology Associates, Springfield
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/28更新 · NCT06846671A Study to Investigate the Safety of Novel Dose Ramp-up Schedule(s) When Initiating Sonrotoclax in Participants Treated for Blood Cancers.
- Washington University School of Medicine, St Louis
被験者募集中第1/2相
18歳以上 · 全性別 · 2026/09/28更新 · NCT06697184A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
- Washington University School of Medicine, St Louis
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/28更新 · NCT06973187A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).
- MidAmerica Cancer Care, LLC ( Site 5426), Kansas City
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/24更新 · NCT05947851A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/BELLWAVE-011)
- MidAmerica Cancer Care, LLC ( Site 0043), Kansas City
被験者募集中第3相
18歳以上 · 全性別 · 2026/09/24更新 · NCT06136559A Phase 1 Study of UB-VV111 With and Without Rapamycin in Relapsed/Refractory CD19+ B-cell Malignancies
- Washington University School of Medicine/Siteman Cancer Center, St Louis
被験者募集中第1相
18歳以上 · 全性別 · 2026/08/17更新 · NCT0652830164Cu-LLP2A for Imaging Hematologic Malignancies
- Washington University School of Medicine, St Louis
被験者募集中早期第1相健康なボランティア歓迎
18歳以上 · 全性別 · 2026/06/17更新 · NCT06636175A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)
- Saint Lukes Hospital of Kansas City /ID# 267270, Kansas City
被験者募集中第3相
18歳以上 · 全性別 · 2026/04/09更新 · NCT06428019A Safety and Efficacy Study Evaluating CTX112 in Subjects With Relapsed or Refractory B-Cell Malignancies
- Washington University, St Louis
被験者募集中第1/2相
18歳以上 · 全性別 · 2025/11/14更新 · NCT05643742A Randomized Phase II Study Of Bruton Tyrosine Kinase Inhibitor With Or Without Venetoclax In Veterans With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
- Kansas City VA Medical Center, Kansas City, MO, Kansas City
被験者募集中第2相
18歳〜80歳 · 全性別 · 2025/10/14更新 · NCT06520098ClinicalTrials.govより、2026/10/05時点のデータを取得。各研究には独自の参加資格があり、参加可否は研究チームが決定します。